Financial Performance - The company's operating revenue for 2023 was CNY 299,871,288.42, representing a year-on-year increase of 21.13% compared to CNY 247,562,432.66 in 2022[20]. - The net profit attributable to shareholders decreased by 34.28% to CNY 61,074,068.07 from CNY 92,931,582.96 in the previous year[23]. - The net cash flow from operating activities fell by 82.29% to CNY 12,958,036.70, down from CNY 73,183,720.97 in 2022[23]. - Basic earnings per share decreased by 38.66% to CNY 0.13 from CNY 0.22 in 2022[22]. - The weighted average return on equity dropped by 5.45 percentage points to 5.14% compared to 10.59% in 2022[22]. - The company's total revenue increased by 21.13% year-on-year, with product sales revenue growing by 148.08%[33]. - The company reported a comprehensive gross margin of 55.89%, indicating a high level of profitability, but faces risks of margin decline due to increased competition and rising costs[102]. - The company achieved operating revenue of CNY 299.87 million, a year-on-year increase of 21.13%[107]. - Net profit attributable to shareholders decreased to CNY 61.07 million, down 34.28% year-on-year[107]. - Total assets at the end of the reporting period reached CNY 1.362 billion, up 2.20% year-on-year[107]. Research and Development - Research and development expenses accounted for 24.68% of operating revenue, down 6.03 percentage points from 30.71% in the previous year[22]. - The company launched new products including Posaconazole enteric-coated tablets and Mesalazine enteric-coated tablets, contributing to revenue growth[22]. - The company obtained approvals for 7 self-developed products and 2 collaborative products during the reporting period[35]. - A total of 9 new patents were applied for, including 6 invention patents and 3 utility model patents[36]. - The company has established three major technology platforms for drug development, focusing on high-tech barrier generics and modified new drugs[40]. - The company has developed three advanced technology platforms: poorly soluble drug solubilization, controlled-release drug formulation, and fixed-dose combination formulation[66]. - The company has filed 9 new patent applications during the reporting period, including 6 invention patents and 3 utility model patents, bringing the total number of intellectual property rights to 70[75]. - The company has a strong R&D team, with over 40% of researchers holding master's degrees or higher, ensuring robust technical capabilities[88]. - The company reported a research and development investment of 20,702.49 million RMB, accounting for 24.68% of its operating income, which is higher than the industry average[156]. Market Expansion and Strategy - The company is actively pursuing international market expansion while enhancing its product pipeline through strategic collaborations[34]. - The company plans to continue expanding its international market presence, particularly with the launch of Mesalazine enteric-coated tablets in the U.S.[114]. - The company plans to enter two new international markets in 2024, aiming for a 15% revenue contribution from these regions[195]. - The company is exploring acquisition opportunities in the tech sector to enhance its product offerings[196]. - The company completed a strategic acquisition of a biotech firm for $500 million, enhancing its product pipeline[195]. - The company is focused on expanding its product offerings through innovative drug delivery systems and enhancing market competitiveness[72]. Risks and Challenges - The company has disclosed various risks it may face in its production and operation processes in the report[5]. - The company faces risks related to raw material price fluctuations, which could impact future performance[95]. - The company is exposed to risks from changes in pharmaceutical industry policies, which could impact its operational performance and market competitiveness[103]. - The company’s cash flow from operating activities decreased by 82.29% to CNY 12.96 million[109]. - The company has accounts receivable of 65.92 million, with potential risks associated with collection as business expands[98]. - The company’s inventory value stands at 84.61 million, indicating a risk of not being able to liquidate stock in a timely manner[99]. Corporate Governance and Compliance - The company held 2 shareholder meetings during the reporting period, reviewing 18 proposals, ensuring compliance with legal and regulatory requirements[178]. - The board of directors convened 8 meetings, reviewing 35 proposals, and maintained a high level of operational independence and compliance[179]. - The supervisory board held 5 meetings, reviewing 21 proposals, ensuring effective oversight of the company's financial and operational activities[181]. - The company adheres to strict information disclosure practices, ensuring transparency and fairness in communication with all shareholders[184]. - The company emphasizes proactive communication with investors through roadshows and earnings briefings to effectively convey its investment value[185]. Product Performance - The sales volume of Mesalazine enteric-coated tablets reached 1,080.54 million pieces, with a production volume of 1,604.04 million pieces, marking a substantial entry into the U.S. market in June 2023[116]. - The sales volume of Ursodeoxycholic acid capsules surged to 3,578.48 million pieces, reflecting a 4,036.97% increase in production volume due to successful bidding in the national centralized procurement[116][117]. - The sales of Buprenorphine extended-release tablets (II) also saw significant growth, benefiting from its inclusion in the national medical insurance directory and ongoing efforts in the U.S. market[117]. - The total sales revenue from the top five customers amounted to 190.27 million yuan, accounting for 63.44% of the annual total sales[123][124]. - The total procurement amount from the top five suppliers was 106.40 million yuan, representing 68.64% of the annual total procurement[126][128].

Financial Performance - The company's operating revenue for Q1 2024 reached ¥111,411,602.18, representing a year-on-year increase of 162.65%[5] - Net profit attributable to shareholders was ¥22,895,905.48, reflecting a significant growth of 196.71% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥21,748,197.24, showing an increase of 304.66% year-on-year[5] - Basic and diluted earnings per share were both ¥0.05, marking a rise of 196.98%[6] - Total operating revenue for Q1 2024 reached ¥111,411,602.18, a significant increase from ¥42,418,265.20 in Q1 2023, representing a growth of 162.5%[22] - Net profit for Q1 2024 was ¥22,895,905.48, up from ¥7,716,721.48 in Q1 2023, marking a growth of 196.5%[23] - The total comprehensive income for the first quarter of 2024 was CNY 22,895,798.14, compared to CNY 7,692,372.68 in the same period of 2023, representing a significant increase[24] - Basic and diluted earnings per share for the first quarter of 2024 were both CNY 0.05, up from CNY 0.02 in the first quarter of 2023, indicating a 150% increase[24] Cash Flow and Liquidity - Cash flow from operating activities amounted to ¥28,776,793.07, an increase of 54.83% due to higher sales revenue[6] - Cash inflows from operating activities totaled CNY 125,100,720.40 in Q1 2024, compared to CNY 68,822,064.13 in Q1 2023, reflecting an increase of approximately 82%[26] - The net cash flow from operating activities was CNY 28,776,793.07 for Q1 2024, compared to CNY 18,585,769.41 in Q1 2023, marking an increase of about 55%[26] - Cash and cash equivalents as of March 31, 2024, amounted to ¥229,422,987.49, a significant decrease from ¥641,783,808.70 as of December 31, 2023[18] - Cash and cash equivalents decreased from ¥127,121,199.56 to ¥10,842,778.87, indicating a significant reduction in liquidity[20] - Cash and cash equivalents at the end of Q1 2024 were CNY 229,422,987.49, down from CNY 449,794,012.15 at the end of Q1 2023, a decrease of approximately 49%[27] Research and Development - Total R&D investment for the quarter was ¥15,454,452.53, which is 41.98% higher than the previous year[6] - Research and development expenses in Q1 2024 amounted to ¥15,454,452.53, compared to ¥10,885,029.09 in Q1 2023, indicating a rise of 42.0%[22] - R&D investment as a percentage of operating revenue decreased by 11.79 percentage points to 13.87% due to significant revenue growth[6] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,353,289,225.61, a slight decrease of 0.61% from the end of the previous year[6] - The company's total assets as of Q1 2024 were ¥1,353,289,225.61, slightly down from ¥1,361,620,252.55 in the previous year[21] - Total liabilities for Q1 2024 were ¥152,469,034.47, compared to ¥151,361,317.13 in Q1 2023, showing a marginal increase of 0.7%[20] - The company's equity attributable to shareholders was ¥1,200,820,191.14, down from ¥1,210,258,935.42 in the previous year, a decrease of 0.4%[21] Shareholder Information - The company has not reported any changes in the top 10 shareholders or the top 10 unrestricted shareholders due to the transfer and lending of shares[16] - The company has maintained a consistent shareholder structure with significant stakes held by major investment partnerships[12] Product Development and Strategy - The newly approved product, Mesalazine enteric-coated sustained-release tablets, received regulatory approval for treating mild to moderate active ulcerative colitis[16] - The company’s strategic focus includes expanding its product offerings and enhancing market presence through new product approvals[16] Other Financial Metrics - The company reported non-recurring gains of ¥1,147,708.24 for the quarter, primarily from asset disposals and government subsidies[7] - The company experienced a credit impairment loss of ¥398,975.62 in Q1 2024, compared to a gain of ¥1,619,789.58 in Q1 2023, indicating a negative shift in credit quality[23] - The company reported a significant increase in contract liabilities, rising to ¥53,319,684.31 from ¥47,610,636.97, an increase of 15.0%[20] - The company received CNY 4,630,030.77 in tax refunds during Q1 2024, a significant increase from CNY 59,190.97 in Q1 2023[26] - The company reported cash received from sales of goods and services of CNY 114,516,373.33 in Q1 2024, compared to CNY 67,128,917.11 in Q1 2023, representing an increase of about 70%[25] - The company paid CNY 55,512,698.36 for goods and services in Q1 2024, compared to CNY 16,150,292.00 in Q1 2023, indicating a substantial increase of approximately 244%[26]

Financial Performance - The company expects to achieve a net profit attributable to the parent company of 23.20 million yuan in Q1 2024, an increase of 15.48 million yuan, representing a year-on-year growth of 201%[10] - The projected operating revenue for Q1 2024 is 111.41 million yuan, which is an increase of 68.99 million yuan, reflecting a year-on-year growth of 163%[10] - In Q1 2023, the company reported an operating revenue of 42.42 million yuan and a net profit attributable to shareholders of 7.72 million yuan[3] - The net profit attributable to shareholders, excluding non-recurring gains and losses, for Q1 2024 is expected to be 21.54 million yuan, an increase of 16.17 million yuan, representing a year-on-year growth of 301%[2] - The significant increase in revenue and profit is attributed to the company's efforts in enhancing product sales and seizing market opportunities[12] Earnings Forecast - The earnings forecast period is from January 1, 2024, to March 31, 2024[10] - The financial data provided in the earnings forecast has not been audited by a registered accounting firm[6] - The company has not identified any major uncertainties that could affect the accuracy of the earnings forecast[13] Investment Risks - The company emphasizes the importance of investors being aware of investment risks related to the preliminary financial data[13] - The official financial data will be disclosed in the formal Q1 2024 report[13]

证券代码：688247 证券简称：宣泰医药 公告编号：2024-015 上海宣泰医药科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份进展情况公告如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2024 年 3 月 29 日，上海宣泰医药科技股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份 3,860,109 股，占公司总股本 453,340,000 股的比例为 0.85%，购买的最高价为 8.98 元/股，最低价为 8.00 元/股，支付的资金总额为人民币 32,314,700.39 元（不含印 花税、交易佣金等交易费用）。 一、回购股份的基本情况 公司于 2024 年 2 月 19 日召开第二届董事会第八次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海 证券交易所股票交易 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-014 重要内容提示： 公司于 2024 年 3 月 14 日接到公司股东栖和创业通知，获悉其所持有公司的 部分股份办理了质押登记及解除质押手续，具体事项如下： 一、本次股份解除质押情况 单位：股 | 股东名称 | 栖和创业 | | --- | --- | | 本次解除质押股份 | 11,900,000 | | 占其所持股份比例 | 32.34% | | 占公司总股本比例 | 2.62% | 上海宣泰医药科技股份有限公司 关于持股 5%以上股东部分股份解除质押及质押的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 截至本公告披露日，上海宣泰医药科技股份有限公司（以下简称"公司"） 股东南京市栖和创业投资合伙企业（有限合伙）（以下简称"栖和创业"） 持有公司股份 36,798,000 股，占公司总股本的 8.12%。 本次解除质押和质押完成后，栖和创业累计质押公司股份 25,750,000 股， 占其持股总数的 69.98%，占公司总股本的 5.68%。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-013 二、实施回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份进展情况公告如下： 2024 年 2 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购 股份 1,271,638 股，占公司总股本 453,340,000 股的比例为 0.28%，购买的最高价 为 8.98 元/股，最低价为 8.00 元/股，支付的资金总额为人民币 10,648,969.53 元 （不含印花税、交易佣金等交易费用）。 截至 2024 年 2 月 29 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购股份 1,271,638 股，占公司总股本 453,340,000 股的比例为 0.28%， 购买的最高价为 8.98 元/股，最低价为 8.00 元/股，支付的资金总额为人民币 10,648,969.53 元（不含印花税、交易佣金等交易费用）。本次回购股份符合法律 法规的规定及公司回购股份方案。 上海宣泰医药科技股份有限公司 关于以集中竞价交易方式回购公司股份 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-012 上海宣泰医药科技股份有限公司 关于以集中竞价交易方式首次回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次回购股份情况公告如下： 2024 年 2 月 26 日，公司通过上海证券交易所交易系统以集中竞价交易方式 首次回购公司股份 268,282 股，占公司总股本 453,340,000 股的比例为 0.06%，回 购成交的最高价为 8.66 元/股，最低价为 8.35 元/股，支付的资金总额为人民币 2,273,869.93 元（不含印花税、交易佣金等交易费用）。本次回购股份符合法律法 规的规定及公司回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定及公司回购股份方案，在回购期限内 根据市场情况择机做出回购决策并予以实施，同 ...

基于对公司未来发展前景的信心、对公司价值的认可和切实履行社会责任， 同时为了进一步建立健全公司长效激励机制，公司拟使用自有资金通过集中竞价 交易方式回购公司已发行的人民币普通股（A 股），本次回购股份的价格不超过 人民币 13.53 元/股（含），回购股份的资金总额不低于人民币 3,500 万元（含）， 不超过人民币 7,000 万元（含）。本次回购股份将在未来适宜时机全部用于员工 持股计划或股权激励。公司如未能在股份回购完成之后 3 年内实施前述用途，未 使用部分将履行相关程序予以注销。 证券代码：688247 证券简称：宣泰医药 公告编号：2024-007 上海宣泰医药科技股份有限公司 第二届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海宣泰医药科技股份有限公司（以下简称"公司"）第二届董事会第八次 会议于 2024 年 2 月 19 日以通讯方式召开。本次会议通知于 2024 年 2 月 14 日 以邮件形式发送。本次会议应出席董事 8 人，实际出席董事 8 人 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-006 上海宣泰医药科技股份有限公司 关于以集中竞价交易方式回购股份方案暨落实"提 质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《公司章程》第二十三条和第二十五条的相关规定，本次回购股份方案 经三分之二以上董事出席的董事会会议决议通过后即可实施，无需提交公司股东 大会审议。 2024 年 2 月 18 日，公司控股股东上海联和投资有限公司向公司董事会提议 公司以自有资金通过上海证券交易所股票交易系统以集中竞价交易方式回购公 司已发行的人民币普通股（A 股），回购的股份将在未来适宜的时机用于员工持 股计划、股权激励，具体用途由公司董事会依据有关法律法规决定。具体内容详 见公司于 2024 年 2 月 19 日在上海证券交易所网站（www.sse.com.cn）披露的《关 于公司控股股东提议回购公司股份的公告》（公告编号：2024-005）。上述提议时 间、程序和董事会审议时间及程序等均符合《上海证券交易所上市 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2024-008 上海宣泰医药科技股份有限公司 关于持股 5%以上股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2024 年 2 月 19 日接到公司股东栖和创业通知，获悉其所持有公司的 部分股份办理了质押登记手续，具体事项如下： 一、本次股份质押情况 单位：股 股东 名称 是 否 为 控 股 股 东 及 其 一 致 行 动人 本次质押股 数 是否为 限售股 是否补 充质押 质押起始 日 质押到 期日 质权人 占其所 持股份 比例 占公司 总股本 比例 质押融 资资金 用途 栖和 创业 否 3,000,000 否 是 2024 年 2 月 8 日 质 权 人 申 请 解 除 质 押 之日止 杭州四时企 业管理合伙 企业（有限 合伙） 8.15% 0.66% 融资 注：本次质押股份未被用作重大资产重组、业绩补偿等事项担保，且相关股 份不存在潜在业绩补偿义务的情况。 截至本公告披露日，上海宣泰医药科技股份有限公司（以下简称" ...